Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Rhea-AI Summary

Acurx Pharmaceuticals (NASDAQ:ACXP), a late-stage biopharmaceutical company focused on developing novel small molecule antibiotics, has announced its participation in The Microcap Conference. The event will be held from January 28-30, 2025, at the Borgata Hotel in Atlantic City, New Jersey. David P. Luci, President & CEO, will deliver the company's presentation on Wednesday, January 29, 2025, at 10 am ET. The company specializes in developing treatments for difficult-to-treat bacterial infections.

STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 28 to January 30, 2025 at the Borgata Hotel, Atlantic City, New Jersey.

Presentation Details:
Acurx Pharmaceuticals, Inc. Presentation: Wednesday, January 29^st at 10 am ET

Interested parties can register to attend here.

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis(anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year. The Company's preclinical pipeline includes development of an oral product candidate for treatment of Acute Bacterial Skin and Skin Structure Infections, upon which a development program for treatment of inhaled anthrax is being planned in parallel.

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2023, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.

Investor Contact: Acurx Pharmaceuticals, Inc.
David P. Luci
President & CEO
Tel: 917-533 1469
Email: davidluci@acurxpharma.com

SOURCE: Acurx Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

When is Acurx Pharmaceuticals (ACXP) presenting at The Microcap Conference 2025?

Acurx Pharmaceuticals (ACXP) will present on Wednesday, January 29, 2025, at 10 am ET at The Microcap Conference.

Where will The Microcap Conference 2025 featuring ACXP be held?

The Microcap Conference will be held at the Borgata Hotel in Atlantic City, New Jersey.

What type of antibiotics is ACXP developing?

ACXP is developing a new class of small molecule antibiotics designed to treat difficult-to-treat bacterial infections.

Who will be presenting for ACXP at The Microcap Conference 2025?

David P. Luci, President & Chief Executive Officer of Acurx Pharmaceuticals, will be presenting at the conference.

What dates will The Microcap Conference 2025 run?

The Microcap Conference will run from January 28 to January 30, 2025.